Emodin nitroxide free radical derivative as well as synthesis method and application thereof
By modifying the nitrogen oxygen radicals of emoldin, the synthesis of high-yield novel emoldin nitrogen oxygen radical derivatives has solved the problem of insufficient anti-hepatocellular activity, achieved effective inhibition and low toxicity on liver cancer cells, and provided New direction for anti-tumor drugs.
Patent Information
- Application Number
- CN202411044573.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-07-31
AI Technical Summary
Although emodin has an inhibitory effect on a variety of cancer cells, its anti-cancer activity is low and it is difficult to effectively inhibit the proliferation of liver cancer cells. It is also poor in the treatment of liver cancer as a blood lipid-lowering drug.
By modifying the No. 3 hydroxyl group of emodin, introducing carbon chain substitution, A3 coupling and esterification reaction mechanisms of different lengths, nitrogen oxygen radicals are introduced into the structure of emodin, and a novel type with high yield and significant anti-hepatocellular activity is synthesized Edhain nitrogen oxygen radical derivative.
The novel emoldin nitrogen oxygen free radical derivative has significant anti-proliferative activity on liver cancer cells, is low in toxicity, has little effect on normal hepatocytes, and is better than the original emoldin, providing a new idea for the preparation of anti-tumor drugs. .
Smart Images

Figure CN118993992A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of organic chemical synthesis, and specifically relates to a rhubarb nitrogen oxide free radical derivative and a synthesis method and application thereof. Background Art
[0002] Rhein is a trihydroxyanthraquinone compound extracted from the Polygonum cuspidatum plant of the Polygonaceae family. It is the active ingredient of the Chinese herbal medicine rhubarb. Studies have found that rhein not only has the effect of lowering blood lipids, but also has an inhibitory effect on cancer cells such as lung cancer and bladder cancer. Although rhein has an inhibitory effect on many cancer cells, its own anti-cancer activity is relatively low.
[0003] Hyperlipidemia is one of the main factors that induce liver cancer. Finding anti-liver cancer active substances from lipid-lowering drugs has become a new strategy for studying anti-liver cancer drugs. As a lipid-lowering drug, emodin has a good effect on lowering blood lipids. Based on its inhibitory effect on cancer cells, it seems to be a new breakthrough point for exploring anti-liver cancer active substances.
[0004] If we can take rhein as a research object and modify it appropriately to obtain a substance with good anti-liver cancer activity, it will be of great significance to the field. Summary of the invention
[0005] In order to solve the above technical problems, the present invention provides a rhamnoides nitroxide free radical derivative and its synthesis method and application, by modifying the 3rd hydroxyl group of rhamnoides, based on different length carbon chain substitution, A 3 Through coupling and esterification reaction mechanism, nitroxide free radicals were introduced into the structure of rhamnosin, and a new rhamnosin nitroxide free radical derivative with high yield and significant anti-hepatocarcin activity was synthesized.
[0006] The technical solution of the present invention is as follows:
[0007] In the first aspect of the present invention, a rhamnosine nitroxide free radical derivative is provided, wherein the structure of the rhamnosine nitroxide free radical derivative is selected from one of general formulas 1 to 3:
[0008]
[0009] The R group is a nitroxide free radical, and R1 and R2 are different active functional groups.
[0010] Preferably, when the rhamnosine nitroxide free radical derivative is of Formula 1 or Formula 3, the nitroxide free radical is selected from any one of Formulas 1 to 4:
[0011]
[0012] When the rhamnosine nitroxide free radical derivative is of general formula 2, the nitroxide free radical is selected from any one of formulas 5 to 6:
[0013]
[0014] Preferably, the rhubarb nitrogen oxide free radical derivative of general formula 1 is prepared by the following method:
[0015] The hydroxyl group at position 3 of rhamnosus was used as the modification site, and hydroxyalkyl side chains of different lengths were introduced at position 3 using bromohydrin through substitution reaction. Then, the nitroxide free radical containing a carboxyl group was connected to the side chain through esterification reaction to synthesize rhamnosus nitroxide free radical derivatives containing different carbon chain lengths, general formula 1.
[0016] Preferably, the method is specifically:
[0017] Rhamnosin and bromohydrin are used as raw materials, Cs2CO3 is used as a catalyst, and DMF (N,N-dimethylformamide) is used as a solvent. The mixture is heated to 50-70°C under the protection of Ar gas and reacted at a constant temperature for 8-10 hours. The solvent is then distilled under reduced pressure to recover the solvent, dissolved with water, and the pH is adjusted to less than 7 with acid. After precipitation, the precipitate is filtered and washed with ethyl acetate to obtain an intermediate of a rhamnosin derivative substituted with carbon chains of different lengths. The intermediate and a carboxyl-containing nitroxide free radical are used as raw materials, EDCI (carbodiimide hydrochloride) and DMAP (4-dimethylaminopyridine) are used as catalysts, and DMF is used as a solvent. The mixture is reacted at room temperature under the protection of Ar gas, and the reaction liquid is extracted with ethyl acetate. The reaction liquid is washed with water, dried, and separated by chromatography to finally obtain a rhamnosin nitroxide free radical derivative of general formula 1.
[0018] Preferably, the bromohydrin is selected from any one of 2-bromoethanol, 3-bromo-1-propanol, 4-bromo-1-butanol, 5-bromo-1-pentanol and 6-bromo-1-hexanol;
[0019] Preferably, the carboxyl-containing nitroxide radical is selected from any one of Formula 1 to Formula 4:
[0020]
[0021] The synthetic route of the rhubarb nitrogen oxide free radical derivative is as follows:
[0022]
[0023] Preferably, the rhubarb nitrogen oxide free radical derivative of general formula 2 is prepared by the following method:
[0024] The hydroxyl group at position 3 of rhamnosine was used as the modification site, and a propynyl group was introduced into its structure by propynyl bromide substitution. 3In the coupling reaction, the synthesized nitroxide free radical containing terminal aldehyde and secondary amine are dehydrated and condensed under the action of a transition metal catalyst to generate the nitroxide free radical derivative of the rhubarb propargylamine type of general formula 2.
[0025] Preferably, the method is specifically:
[0026] First, using rhamnol and propargyl bromide as raw materials, DMF as solvent, and anhydrous K2CO3 as catalyst, under the protection of Ar gas, heating to 60-80°C for reaction for 4 hours, TLC detection until the reaction is complete, extraction, washing, drying and column chromatography separation and purification are performed to obtain a propargyl-substituted rhamnol derivative; then, using a propargyl-substituted rhamnol derivative, an aldehyde-containing nitrogen oxide free radical and a secondary amine as raw materials, toluene as solvent, and CuBr as catalyst, under the protection of Ar gas, heating to 70-90°C for reaction for 7-9 hours, TLC detection until the reaction is complete, column chromatography is used for separation and purification, and finally the rhamnol nitrogen oxide free radical derivative of general formula 2 is obtained.
[0027] Preferably, the aldehyde-containing nitroxide free radical is selected from any one of Formula 5 to Formula 6:
[0028]
[0029] Preferably, the secondary amine is selected from any one of Formula 7 to Formula 19:
[0030]
[0031]
[0032] The synthetic route of the rhubarb nitrogen oxide free radical derivative is as follows:
[0033]
[0034] Preferably, the rhubarb nitrogen oxide free radical derivative of general formula 3 is prepared by the following method:
[0035] The hydroxyl group at position 3 of rhamnoides was used as the modification site, and the synthesized carboxyl-containing nitroxide free radical was directly connected to the rhamnoides structure through dehydration condensation to obtain the rhamnoides nitroxide free radical derivative.
[0036] Preferably, the method is specifically:
[0037] Rhamnosin and carboxyl-containing nitroxide free radicals are used as raw materials, DMF is used as solvent, EDCI and DMAP are used as catalysts, and the reaction is carried out under Ar gas protection for 6 to 8 hours, and TLC tracking and monitoring is performed until the reaction is complete. After the reaction is terminated, extraction, washing, drying and filtration are performed, and separation and purification by silica gel column chromatography are finally obtained to obtain the rhamnosin nitroxide free radical derivative of general formula 3;
[0038] Preferably, the carboxyl-containing nitroxide free radical is selected from any one of Formulas 1 to 4 above.
[0039] The synthetic route of the rhubarb nitrogen oxide free radical derivative is as follows:
[0040]
[0041] In the second aspect of the present invention, there is provided a use of the above-mentioned rhein nitrogen oxide free radical derivative in anti-tumor drugs.
[0042] Preferably, the anti-tumor drug is an anti-liver cancer drug.
[0043] The beneficial effects of the present invention are:
[0044] (1) The present invention uses rhubarb, a lipid-lowering drug substance of traditional Chinese medicine, as the research object, selects its 3-hydroxyl group as the modification site, and based on the substitution of different carbon chain lengths, A 3 Based on the reaction mechanisms of coupling, esterification and pharmacophore splicing, six active intermediate nitroxide free radicals were introduced into the structure of rhubarb, and 50 rhubarb nitroxide free radical derivatives in three series and 8 other derivatives were designed and synthesized. Several synthetic methods for new rhubarb nitroxide free radical derivatives with mild reaction conditions, environmental friendliness and high yield were established.
[0045] (2) The novel nitrogen oxide free radical derivative of emodin provided by the present invention has low toxicity to normal liver cells, significant anti-proliferation activity against liver cancer cells, and is a novel active molecule with better effect than emodin, providing a new idea for the preparation of anti-tumor drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0046] Figure 1 The effect of rhamnosine nitroxide derivative 8e on the migration ability of HepG2 cells;
[0047] Figure 2 The effect of rhamnosin nitroxide derivative 8e on the cell cycle distribution of HepG2 cells;
[0048] Figure 3 The effect of rhamnosin and its nitroxide derivatives on the morphology of HepG2 cells, where A represents the blank control group, and B represents rhamnosin and nitroxide derivatives 1e and 8e groups, the left picture is magnified at 3000×, and the right picture is magnified at 8000×;
[0049] Figure 4 Effects of rhamnosin and its nitroxide derivatives on Fe 2+ The impact of levels;
[0050] Figure 5The effect of rhamnosin and its nitroxide derivatives on the expression of MDA in HepG2 cells;
[0051] Figure 6 The effect of rhamnosin and its nitroxide derivatives on the expression of GSH in HepG2 cells;
[0052] Figure 7 The effect of rhamnosine nitroxide derivatives on ROS levels in HepG2 cells;
[0053] Figure 8 The effect of the rhamnosin nitroxide free radical derivative 8e on the mRNA expression of SLC7A11 and GPX4; Figure A represents the effect on GPX4, and Figure B represents the effect on SLC7A11;
[0054] Fig. 9 The effect of rhamnosin nitroxide derivative 8e on the expression of proteins xCT and GPX4 in HepG2 cells;
[0055] Note: Figures 4 to 6 , Figure 8-Figure 9 Compared with the blank control group, *p<0.05, **p<0.01; in the figure, Control represents the blank control group, Sorafenib refers to sorafenib, and Emodin refers to emodin. DETAILED DESCRIPTION
[0056] In order to enable those skilled in the art to better understand the present invention, the present invention is further described in conjunction with specific implementation methods.
[0057] Example 1
[0058] A rhamnoides nitroxide free radical derivative, wherein the rhamnoides nitroxide free radical derivative has a structure of general formula 1:
[0059]
[0060] The rhamnosine nitrogen oxide free radical derivative of general formula 1 is prepared by the following method:
[0061] (1) Rheum officinale and five bromoalcohols, namely, 2-bromoethanol, 3-bromo-1-propanol, 4-bromo-1-butanol, 5-bromo-1-pentanol and 6-bromo-1-hexanol, are used as raw materials, Cs2CO3 is used as a catalyst, and DMF is used as a solvent. The mixture is heated to 60°C under the protection of Ar gas and stirred for 9 hours. The solvent is then recovered by vacuum distillation, dissolved with water, and the pH value is adjusted to 5 with concentrated hydrochloric acid. After precipitation, the precipitate is filtered and washed with ethyl acetate to obtain a powdery compound, namely, the intermediates z1-z5 of rheum officinale derivatives substituted with different carbon chains.
[0062] (2) The five intermediates and four kinds of carboxyl-containing nitrogen oxide free radicals such as 4-carboxyl-TEMPO were used as raw materials, EDCI and DMAP were used as catalysts, and DMF was used as solvent. The reaction was carried out at room temperature for 24 hours under the protection of Ar gas. The reaction solution was extracted with ethyl acetate, washed with water, dried over anhydrous Na2SO4, and separated by silica gel column chromatography to finally obtain the target compound.
[0063] Example 1-1
[0064] The only difference from Example 1 is:
[0065] (1), heated to 50°C under Ar gas protection and stirred for 9 h;
[0066] (2), the reaction was carried out at room temperature for 12 h under the protection of Ar gas.
[0067] The other steps are the same as those in Example 1.
[0068] Example 1-2
[0069] The only difference from Example 1 is:
[0070] (1), heated to 70°C under Ar gas protection and stirred for 9 h;
[0071] (2), the reaction was carried out at room temperature for 18 h under the protection of Ar gas. The other steps were the same as those in Example 1.
[0072] Examples 1-3
[0073] The only difference from Example 1 is:
[0074] (2), the reaction was carried out at room temperature for 30 h under the protection of Ar gas. The other steps were the same as those in Example 1.
[0075] The conditions in Examples 1-1, 1-2, and 1-3 can also achieve the purpose of synthesizing the target product, but the highest yield among them is only about 45%. The yield of Example 1 is higher than that of Examples 1-1, 1-2, and 1-3, which is about 55%. Therefore, Example 1 is preferred as the reaction condition. Similarly, in the following examples, the highest yield is also selected as the reaction condition, see Examples 2 and 3 for details.
[0076] The general formula 1 of the rhubarb nitrogen oxide free radical derivative obtained in Example 1 and the specific structure of the raw materials are shown in Table 1:
[0077] Table 1 Rheum officinale nitrogen oxide free radical derivatives general formula 1 and raw material structure
[0078]
[0079]
[0080]
[0081] Example 2
[0082] A rhamnoides nitroxide free radical derivative, wherein the rhamnoides nitroxide free radical derivative has a structure of general formula 2:
[0083]
[0084] The rhubarb nitrogen oxide free radical derivative of general formula 2 is prepared by the following method:
[0085] (1) First, using rhamnosine and propargyl bromide as raw materials, DMF as solvent, and anhydrous K2CO3 as catalyst, the mixture was heated to 70°C and magnetically stirred for 4 hours under the protection of Ar gas, and the reaction was completed by TLC detection. The rhamnosine derivative substituted with propargyl was obtained by extraction, washing, drying, and column chromatography separation and purification;
[0086] (2) Using propynyl-substituted rhamnosine derivatives, 4-formyl-TEMPO (e) and 3-formyl-2,2,5,5-tetramethylpyrrolidine-1-nitroxide free radical (f) and 20 secondary amines such as di-n-propylamine, 4-(trifluoromethyl)piperidine and morpholine as raw materials, toluene as solvent, CuBr as catalyst, heated to 80°C under Ar gas protection and magnetic stirring for about 8 hours, TLC detection until the reaction is complete, and column chromatography for separation and purification to finally obtain the target compound.
[0087] Example 2-1
[0088] The only difference from Example 2 is:
[0089] (1), heated to 60 °C under Ar gas protection and magnetically stirred for 4 h;
[0090] (2) The mixture was heated to 60 °C and stirred with magnetic stirring for about 8 h under the protection of Ar gas.
[0091] Example 2-2
[0092] The only difference from Example 2 is:
[0093] (1), heated to 80 °C under the protection of Ar gas and magnetically stirred for 4 h;
[0094] (2), under the protection of Ar gas, the mixture was heated to 80 °C and stirred with magnetic stirring for about 6 h.
[0095] Example 2-3
[0096] In (1), under the protection of Ar gas, the reaction was heated to 100° C. and magnetically stirred for 4 h. In (2), under the protection of Ar gas, the reaction was heated to 60° C. and magnetically stirred for about 7 h.
[0097] Embodiment 2-4
[0098] In (1), under the protection of Ar gas, the mixture was heated to 120° C. and magnetically stirred for 4 h. In (2), under the protection of Ar gas, the mixture was heated to 60° C. and magnetically stirred for about 6 h.
[0099] Embodiment 2-5
[0100] In (1), under the protection of Ar gas, the mixture was heated to 80° C. and magnetically stirred for 4 h. In (2), under the protection of Ar gas, the mixture was heated to 80° C. and magnetically stirred for about 6 h.
[0101] Embodiment 2-6
[0102] The only difference from Example 2 is:
[0103] In (1), under the protection of Ar gas, the mixture was heated to 80° C. and magnetically stirred for 4 h. In (2), under the protection of Ar gas, the mixture was heated to 80° C. and magnetically stirred for about 7 h.
[0104] Embodiment 2-7
[0105] The only difference from Example 2 is:
[0106] In (1), under the protection of Ar gas, the mixture was heated to 80° C. and magnetically stirred for 4 h. In (2), under the protection of Ar gas, the mixture was heated to 100° C. and magnetically stirred for about 6 h.
[0107] Embodiment 2-8
[0108] The only difference from Example 2 is:
[0109] In (1), under the protection of Ar gas, the mixture was heated to 60° C. and magnetically stirred for 4 h. In (2), under the protection of Ar gas, the mixture was heated to 120° C. and magnetically stirred for about 6 h.
[0110] Embodiment 2-9
[0111] The only difference from Example 2 is:
[0112] (1), heated to 100 °C under the protection of Ar gas and magnetically stirred for 4 h;
[0113] (2) The reaction was heated to 60 °C and stirred with magnetic stirring for about 6 h under the protection of Ar gas.
[0114] Taking Example 2 as an example, the obtained rhubarb nitrogen oxide free radical derivative general formula 2 and the specific structure of the raw materials are shown in Table 2 and Table 3:
[0115] Table 2 Rheum officinale propargylamine nitrogen oxide free radical derivatives general formula 2 and raw material structure
[0116]
[0117]
[0118]
[0119] Table 3 Rheum officinale propargylamine nitrogen oxide free radical derivatives general formula 2 and raw material structure
[0120]
[0121]
[0122]
[0123] Example 3
[0124] A rhamnoides nitroxide free radical derivative, wherein the rhamnoides nitroxide free radical derivative has a structure of the following general formula 3:
[0125]
[0126] The rhubarb nitrogen oxide free radical derivative of general formula 3 is prepared by the following method:
[0127] Four kinds of carboxyl-containing nitrogen oxide free radicals, such as rhein and 4-carboxy-TEMPO, were used as raw materials, DMF was used as solvent, EDCI and DMAP were used as catalysts, and the reaction was carried out under magnetic stirring at room temperature for 7 hours under Ar gas protection. TLC tracking and monitoring was carried out until the reaction was complete. After the reaction was terminated, the target compound was finally obtained by extraction, washing, drying and filtration, and separation and purification by silica gel column chromatography.
[0128] Example 3-1
[0129] The only difference from Example 3 is that:
[0130] The reaction was carried out under Ar gas protection at room temperature with magnetic stirring for 5 h. The other steps were the same as those in Example 3.
[0131] Example 3-2
[0132] The reaction was carried out under Ar gas protection at room temperature with magnetic stirring for 9 h. The other steps were the same as those in Example 3.
[0133] Example 3-3
[0134] The reaction was carried out under Ar gas protection at room temperature with magnetic stirring for 12 h. The other steps were the same as those in Example 3.
[0135] The general formula 3 of the rhubarb nitrogen oxide free radical derivative obtained in Example 3 and the specific structure of the raw materials are shown in Table 4:
[0136] Table 4 Rheum officinale nitrogen oxide free radical derivatives general formula 3 and raw material structure
[0137]
[0138] Test Example 1 Evaluation of the Anti-liver Cancer Activity of Rheum Officinale Nitrogen Oxygen Free Radical Derivatives
[0139] The MTT method was used to determine the anti-proliferative activity of nitroxide free radicals, emodin and its nitroxide free radical derivatives on liver cancer cells and the cytotoxicity on normal cells L02 in Examples 1, 2 and 3. The results are shown in Table 5:
[0140] Table 5 Antiproliferative activity of nitroxide free radicals, emodin and its nitroxide free radical derivatives on liver cancer cells and cytotoxicity on normal cells L02
[0141]
[0142]
[0143] As shown in Table 5, the six nitroxide free radicals and emodin all showed good antiproliferative activity against HepG2 liver cancer cells. 50 The values were between 25.40 and 50.01 μM, and the IC 50 The value was 59.55 μM. The antiproliferative ability of the new rhamnosin nitroxide free radical derivatives was different. There were 31 new compounds with IC 50 The value was less than 59.55 μM, and the antiproliferative ability was significantly improved compared with that of flavin. The IC values of 1e, 8e and other five new compounds were 50 The value was lower than 10 μM, showing good antiproliferative activity. Cytotoxicity results showed that 26 of the 31 novel compounds had an IC 50 Rheum officinale
[0144] (IC 50 =44.63μM), showing low toxicity, and their selectivity index SI was greater than that of emodin (0.75). The selectivity indexes of derivatives 1e and 8e were 8.13 and 14.87, respectively, showing good selective anti-liver cancer cell proliferation activity. The low-toxic and significantly active anti-liver cancer active molecules 1e and 8e were screened out.
[0145] The results of cell wound healing experiments showed that rheumatoid artemisia and its derivatives 1e and 8e had a certain inhibitory effect on the migration and repair of liver cancer cells HepG2, and showed a dose-dependent effect. The results of cell cycle experiments showed that rheumatoid artemisia and its derivatives 1e and 8e could block HepG2 cells in the G1 / S phase in a dose-dependent manner, thereby exerting anti-tumor activity. Figure 1-2 As shown in Tables 6 and 7.
[0146] Table 6 Effects of rhamnosine nitroxide derivative 8e on the migration ability of HepG2 cells
[0147]
[0148] Table 7 Effects of rhamnosine nitroxide derivative 8e on HepG2 cell cycle distribution
[0149]
[0150]
[0151] Experimental Example 2 Study on the anti-liver cancer mechanism of rhubarb nitroxide free radical derivatives
[0152] Transmission electron microscopy observations revealed that after intervention with emodin and its nitroxide free radical derivatives 1e and 8e, the mitochondrial morphology of liver cancer cells in each group changed significantly, with a reduction in volume, an increase in double membrane density, and a decrease in mitochondrial cristae, which are consistent with the characteristics of ferroptotic mitochondria. The higher the concentration, the more obvious the changes. Figure 3 By measuring the Fe 2+ , MDA, GSH and ROS levels in HepG2 cells. Compared with the blank control group, rhamnosine and its nitroxide free radical derivatives 1e and 8e could significantly increase the intracellular Fe 2+ , MDA and ROS levels (p<0.01), and reduced GSH level (p<0.01), and showed a dose-dependent manner. Figure 4 to Figure 7 As shown in Table 8 (Control represents the blank control group, Sorafenib refers to sorafenib, and Emodin refers to emodin). RT-qPCR and WB results showed that SLC7A11 and GPX4 were expressed in HepG2 cells, and the mRNA and protein expression levels of SLC7A11 and GPX4 were significantly reduced after drug intervention (p<0.01). Figure 8-Figure 9 As shown in Table 9, the effects of rheum officinale nitrogen oxide free radical derivatives 1e and 8e are more significant than rheum officinale.
[0153] Table 8 Effects of rhamnosin and its nitroxide derivative 8e on Fe in HepG2 cells 2+level, MDA expression in HepG2 cells, GSH expression in HepG2 cells, and ROS level in HepG2 cells
[0154]
[0155] Table 9 Effects of rhubarb nitroxide derivative 8e on the expression of SLC7A11 and GPX4 mRNA and the expression of proteins xCT and GPX4 in HepG2 cells
[0156]
[0157] As can be seen from Tables 8 and 9, the rhamnosine nitroxide derivatives 1e and 8e inhibit System Xc-downregulate SLC7A11, reduce the uptake of intracellular cystine, reduce GSH synthesis, indirectly inhibit the activity of GPX4, induce the abnormal accumulation of lipid ROS, and upregulate the Fe2+ level, ultimately leading to ferroptosis of liver cancer cells.
Claims
1. A rhamnoides nitroxide free radical derivative, characterized in that: The structure of the rhamnosine nitroxide free radical derivative is selected from any one of Formulas 1 to 3: The R group is a nitroxide free radical, and R1 and R2 are different active functional groups.
2. The method for synthesizing the rheum nitroxide free radical derivative according to claim 1, characterized in that: The following steps are involved: The hydroxyl group at position 3 of rhamnosus was used as the modification site, and hydroxyalkyl side chains of different lengths were introduced at position 3 using bromohydrin through substitution reaction. Then, the nitroxide free radical containing a carboxyl group was connected to the side chain through esterification reaction to synthesize rhamnosus nitroxide free radical derivatives containing different carbon chain lengths, general formula 1.
3. The synthesis method according to claim 2, characterized in that The method is specifically as follows: Rhamnosin and bromohydrin are used as raw materials, Cs2CO3 is used as a catalyst, and DMF is used as a solvent. The mixture is heated to 50-70°C under the protection of Ar gas and reacted at a constant temperature for 8-10 hours. The solvent is then distilled under reduced pressure to recover the solvent, dissolved with water, and the pH is adjusted to less than 7 with acid. After precipitation, the precipitate is filtered and washed with ethyl acetate to obtain an intermediate of a rhamnosin derivative substituted with carbon chains of different lengths. The intermediate and a carboxyl-containing nitroxide free radical are used as raw materials, EDCI and DMAP are used as catalysts, and DMF is used as a solvent. The mixture is reacted at room temperature under the protection of Ar gas, and the reaction liquid is extracted with ethyl acetate. The reaction liquid is washed with water, dried, and separated by chromatography to finally obtain a rhamnosin nitroxide free radical derivative of general formula 1.
4. The synthesis method according to claim 2, characterized in that The bromoalcohol is selected from any one of 2-bromoethanol, 3-bromo-1-propanol, 4-bromo-1-butanol, 5-bromo-1-pentanol and 6-bromo-1-hexanol; The carboxyl-containing nitroxide free radical is selected from any one of Formula 1 to Formula 4:
5. The method for synthesizing the rhein nitrogen oxide free radical derivative according to claim 1, characterized in that: The following steps are involved: The hydroxyl group at position 3 of rhamnosine was used as the modification site, and a propynyl group was introduced into its structure by propynyl bromide substitution. 3 In the coupling reaction, the synthesized nitroxide free radical containing terminal aldehyde and secondary amine are dehydrated and condensed under the action of a transition metal catalyst to generate the nitroxide free radical derivative of the rhubarb propargylamine type of general formula 2.
6. The synthesis method according to claim 5, characterized in that The method is specifically as follows: First, using rhamnol and propargyl bromide as raw materials, DMF as solvent, and anhydrous K2CO3 as catalyst, under the protection of Ar gas, heating to 60-80°C for reaction for 4 hours, TLC detection until the reaction is complete, extraction, washing, drying and column chromatography separation and purification are performed to obtain a propargyl-substituted rhamnol derivative; then, using a propargyl-substituted rhamnol derivative, an aldehyde-containing nitrogen oxide free radical and a secondary amine as raw materials, toluene as solvent, and CuBr as catalyst, under the protection of Ar gas, heating to 70-90°C for reaction for 7-9 hours, TLC detection until the reaction is complete, column chromatography is used for separation and purification, and finally the rhamnol nitrogen oxide free radical derivative of general formula 2 is obtained.
7. The synthesis method according to claim 6, characterized in that The aldehyde-containing nitroxide free radical is selected from any one of Formula 5 to Formula 6: The secondary amine is selected from any one of Formula 7 to Formula 19:
8. The method for synthesizing the rhein nitrogen oxide free radical derivative according to claim 1, characterized in that: The following steps are involved: The hydroxyl group at position 3 of rhamnosus was used as the modification site, and the synthesized carboxyl-containing nitroxide free radical was directly connected to the rhamnosus structure through dehydration condensation to obtain the rhamnosus nitroxide free radical derivative of general formula 3.
9. The synthesis method according to claim 8, characterized in that The method is specifically as follows: Rhamnosin and carboxyl-containing nitroxide free radicals are used as raw materials, DMF is used as solvent, EDCI and DMAP are used as catalysts, and the reaction is carried out for 6 to 8 hours under the protection of Ar gas, and TLC tracking and monitoring is performed until the reaction is complete. After the reaction is terminated, extraction, washing, drying and filtration are performed, and separation and purification by silica gel column chromatography are finally obtained to obtain the rhamnosin nitroxide free radical derivative of general formula 3; The carboxyl-containing nitroxide free radical is selected from any one of Formula 1 to Formula 4:
10. Use of the rheum nitroxide free radical derivative according to claim 1 or the rheum nitroxide free radical derivative synthesized by the synthesis method according to any one of claims 2 to 9 in antitumor drugs, characterized in that: The anti-tumor drug is an anti-liver cancer drug.
Citation Information
Patent Citations
Emodin derivates and application thereof in anti-cancer medicine preparation
CN101362702A
Rheum emodin derivative and application thereof
CN102391095A
